Digestery
Longevity supplements › Metformin and Aging › Studies

Population study: one-time survey

Study of 20314 UK adults: metformin use showed no clear link to better thinking

Antal and colleagues · eLife · 2022

Original title: Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No difference

Type 2 diabetes was linked to brain shrinkage and weaker thinking, overlapping with aging effects. Metformin treatment status was not associated with improved neurocognitive outcomes.

The study at a glance

Type of study
Population study: one-time survey
Who or what was studied
20,314 people · Adults aged 50 to 80 in the UK Biobank, including 1012 with type 2 diabetes (498 on metformin alone)
What was tested
Brain scans and thinking tests in people with diabetes vs without; then metformin-treated vs untreated people with diabetes
What it measured
Several kinds of outcomes
Who has a stake
Company stake
One author sits on a Novo Nordisk data monitoring committee; others report fees from drug firms, said to be unrelated to this work.
Journal
eLife, 2022
Source
PubMed record 35608247. This page is based on the abstract only.

How much this study counts

  • –A one-time snapshot: it shows a link, not a cause, and cannot show which came first.
  • ✓Large: 20,314 people.
  • •Measured several kinds of outcomes.
  • –Company stake: One author sits on a Novo Nordisk data monitoring committee; others report fees from drug firms, said to be unrelated to this work.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

    ↑ This study is the ringed dot

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 7 papers on the same step: 6 benefit, 1 no difference. This one found no difference. It differs from most of them.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 1 field after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.